News

Horizon and Ubiquigent Enter into Collaboration Agreement


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Horizon and Ubiquigent Enter into Collaboration Agreement

26/05/2016


Horizon’s X-MAN cell lines to be made available in conjunction with Ubiquigent’s ubiquitin-related Drug Discovery Services


Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies including cell models, today announced it has entered into a Collaboration Agreement with Ubiquigent Ltd (“Ubiquigent”). Under the terms of the agreement, Ubiquigent will be able to utilize Horizon’s X-MAN® cell lines as part of its ubiquitin system focused Drug Discovery Services.

The ubiquitin system offers many new drug discovery target opportunities across multiple therapeutic areas including cancer, cardiovascular and metabolic, neurological and musculoskeletal, and infection and immunity. The modification of proteins through the attachment of the protein ubiquitin, or ubiquitin-like proteins (Ubls), is key to the control of cellular protein homeostasis as well as signalling, similar to the critical role played by phosphorylation (approximately 30% of commercial drug discovery programmes target phosphorylation enzymes), and holds similar potential for clinical utility.

Ubiquigent provides access to a full suite of Drug Discovery Services, high quality Research Tools and Chemistry required to support its commercial and academic partners in pursuing ubiquitin system-focused drug discovery programmes, and in undertaking basic research.

Horizon designs and engineers genetically-modified cells. The X-MAN cell line range represents an extensive bank of genetically defined and highly validated human cell line models that accurately exhibit disease-causing genetics and are applied in research and clinical applications to advance human health.

This collaboration will provide novel and more complete research solutions to support commercial and academic partners as they undertake basic research and pursue ubiquitin system focused drug discovery programs. Together, both companies will now provide a more integrated offering to the growing drug discovery market.

Thomas Moser, VP Products, Horizon Discovery Group plc, commented: “By partnering, Horizon and Ubiquigent are now in a position to provide a more comprehensive package to academic and commercial researchers working in the promising ubiquitin system area. This agreement further underscores the value of Horizon’s X-MAN cell line collection and highlights the impact our models are having on the research community.”

Jason Mundin, Commercial Director, Ubiquigent Ltd., said: “Ubiquigent’s first class experience and deep technical capabilities have enabled us to develop an extensive and highly valuable ubiquitin system focussed Drug Discovery Service platform for our clients. We are pleased now to provide access Horizon’s unique collection of gene edited cell lines to further enable and expand our service offering.”

Financial details of the agreement are not disclosed.


ENDS


For further information on Horizon, please contact:

Zyme Communications
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com


For further information on Ubiquigent, please contact:

Ubiquigent Limited
Jason Mundin, Commercial Director
Tel: +44 (0)7976 000683
Email: jason.mundin@ubiquigent.com


About Horizon Discovery Group plc www.horizondiscovery.com/

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalog products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c1,400 unique research organizations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalized basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.


About Ubiquigent Ltd. http://www.ubiquigent.com/

Ubiquigent Limited is a specialist developer and supplier of Drug Discovery Services, high quality Research Tools and Chemistry to the life science research community worldwide. Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.

Ubiquigent benefits from high calibre backing including from IP Group plc, US investors, the UK Medical Research Council, and the University of Dundee. The company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.
 

© Catalyst Innovation Portal 2019